Rösch AG Medizintechnik
Ad hoc-Service: Rösch AG Medizintechnik english

Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Approval by French health authority of needle-free injection system INJEX(tm) Rösch AG Medizintechnik (WKN 529140), Berlin, has won the acceptance of cost- funding institutions in the health system for the needle-free injection system INJEX(tm). The “Comite economique des produits de sante, Departement des Dispositifs Medicaux”, in Paris / France has agreed to fund the costs for both the INJEX(tm) system itself and the consumption material in France. Costs will be refunded under the prerequisite of the prescription by the doctor to administer insulin. The successful generation of new markets in Europe is the major factor behind the realisation of the company’s ambition for the current financial year. The approval from the French health authority provides an excellent basis for this. In addition, the approval from France gives a further boost to the test procedure for the approval of the INJEX(tm) system in Germany. It has been promised to the company to receive a decision on this within the current financial year. Board of Directors For further information, please contact: Rösch AG Medizintechnik Buckower Damm 114, 12349 Berlin Tel. +49 (30) 66 79 15 – 37 Fax +49 (30) 66 79 15 – 66 E-mail: vorstand@roesch-ag.de Internet: www.roesch-ag.de end of ad hoc announcement (c) DGAP 15.05.2001 Issuer’s information/explanatory remarks concerning this ad hoc announcement: Now that the cost-funding institutions of the Dutch and Norwegian health authorities are already refunding the costs, the latest agreement to bear the costs of the INJEX(tm) system represents another important milestone in this product launch. The company is expecting regulations on the refunding of costs in Germany to be issued in the 4th quarter of the current financial year, 2000/2001. The directory of adjuvants for which the costs can be refunded by the German health insurers does not yet include any application aids (product group 03). According to information from the IKK Bundesverband (Association of German Health Insurers), the leading associations of health insurers are currently drawing up a list of all individual application aids (including INJEX) with corresponding fixed costs for product group 03 of the directory of adjuvants (@§ 128, 36 and 213 of the code of social law). At the request of the medical services of the leading associations, Rösch AG submitted full documentation on March 15, 2001. In the short-term Rösch AG will begin an extensive marketing campaign for the INJEX(tm) system. This campaign will initially be conducted in Germany and France. In Germany, the campaign will complement the company’s “healthy diabetics” initiative, which is supported by the Deutscher Diabetiker Bund (German Diabetics Association) among others. ——————————————————————————– WKN: 529 140; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Stuttgart, Hannover 151340 Mai 01